• 1
    Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43( Suppl.): S99-S112.
  • 2
    Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290: G852-G858.
  • 3
    Xu JJ, Diaz D, O'Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 2004; 150: 115-128.
  • 4
    Matsuda Y, Ikegami F, Kobayashi K, Hasumura Y, Takada A. Phospholipidosis caused by diethylaminoethoxyhexestrol [in Japanese]. Saishin Igaku 1971; 26: 2263-2267.
  • 5
    Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 1997; 25: 53-60.
  • 6
    Donato MT, Martinez-Romero A, Jimenez N, Negro A, Herrera G, Castell JV, et al. Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol Interact 2009; 181: 417-423.
  • 7
    Moya M, Gomez-Lechon MJ, Castell JV, Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact 2010; 184: 376-387.
  • 8
    Guillouzo A, Guguen-Guillouzo C. Evolving concepts in liver tissue modeling and implications for in vitro toxicology. Expert Opin Drug Metab Toxicol 2008; 4: 1279-1294.
  • 9
    Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006; 34: 75-83.
  • 10
    Antherieu S, Chesne C, Li R, Camus S, Lahoz A, Picazo L, et al. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 2010; 38: 516-525.
  • 11
    Freneaux E, Labbe G, Letteron P, The Le D, Degott C, Geneve J, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988; 8: 1056-1062.
  • 12
    Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990; 21: 59-67.
  • 13
    Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67: 101-154.
  • 14
    Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99: 15655-15660.
  • 15
    Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007; 45: 957-967.
  • 16
    Barrans A, Collet X, Barbaras R, Jaspard B, Manent J, Vieu C, et al. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem 1994; 269: 11572-11577.
  • 17
    Fisch C, Robin MA, Letteron P, Fromenty B, Berson A, Renault S, et al. Cell-generated nitric oxide inactivates rat hepatocyte mitochondria in vitro but reacts with hemoglobin in vivo. Gastroenterology 1996; 110: 210-220.
  • 18
    Lambert CB, Spire C, Claude N, Guillouzo A. Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 2009; 234: 345-360.
  • 19
    De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-Dall'Antonia F, Pazienza V, et al. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest 2007; 87: 792-806.
  • 20
    Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009; 24: 830-840.
  • 21
    Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A, et al. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990; 255: 1371-1376.
  • 22
    Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol 1987; 65: 360-364.
  • 23
    Rotmensch HH, Belhassen B, Swanson BN, Shoshani D, Spielman SR, Greenspon AJ, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 1984; 101: 462-469.
  • 24
    Whalley PJ, Adams RH, Combes B. Tetracycline toxicity in pregnancy. Liver and pancreatic dysfunction. JAMA 1964; 189: 357-362.
  • 25
    Nguyen P, Leray V, Diez M, Serisier S, Le Bloc'h J, Siliart B, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 2008; 92: 272-283.
  • 26
    Moreau A, Teruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, et al. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 2009; 49: 2068-2079.
  • 27
    Fujimura H, Murakami N, Kurabe M, Toriumi W. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J Appl Toxicol 2009; 29: 356-363.
  • 28
    Fukushima T, Kikkawa R, Hamada Y, Horii I. Genomic cluster and network analysis for predictive screening for hepatotoxicity. J Toxicol Sci 2006; 31: 419-432.
  • 29
    Zidek N, Hellmann J, Kramer PJ, Hewitt PG. Acute hepatotoxicity: a predictive model based on focused illumina microarrays. Toxicol Sci 2007; 99: 289-302.
  • 30
    Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1281-G1287.
  • 31
    Motomura W, Inoue M, Ohtake T, Takahashi N, Nagamine M, Tanno S, et al. Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem Biophys Res Commun 2006; 340: 1111-1118.
  • 32
    Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, Londos C. Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. J Lipid Res 1997; 38: 2249-2263.
  • 33
    Zhai W, Xu C, Ling Y, Liu S, Deng J, Qi Y, et al. Increased lipolysis in adipose tissues is associated with elevation of systemic free fatty acids and insulin resistance in perilipin null mice. Horm Metab Res; 42: 247-253.
  • 34
    Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001; 98: 7522-7527.
  • 35
    Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Siren J, Hamsten A, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007; 56: 2759-2765.
  • 36
    Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005; 83: 282-292.
  • 37
    Donato MT, Jimenez N, Serralta A, Mir J, Castell JV, Gomez-Lechon MJ. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro 2007; 21: 271-276.
  • 38
    Fiatarone JR, Coverdale SA, Batey RG, Farrell GC. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. J Gastroenterol Hepatol 1991; 6: 585-590.
  • 39
    Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res 2006; 34: 57-63.
  • 40
    Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998; 28: 410-416.
  • 41
    Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1993; 21: 978-985.
  • 42
    Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000; 49: 244-253.
  • 43
    Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984; 86: 926-936.
  • 44
    Lullmann H, Lullmann-Rauch R, Wassermann O. Drug-induced phospholipidosis II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol 1975; 4: 185-218.
  • 45
    Carman GM, Han GS. Roles of phosphatidate phosphatase enzymes in lipid metabolism. Trends Biochem Sci 2006; 31: 694-699.
  • 46
    Atienzar F, Gerets H, Dufrane S, Tilmant K, Cornet M, Dhalluin S, et al. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci 2007; 96: 101-114.